### PATENT COOPERATION TREATY

#### From the INTERNATIONAL BUREAU

## **PCT**

NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis.3(c) and 72.2)

То:	•
SAEKI, Norio 4th Floor, Aminos 15-8, Nihonbashi Chuo-ku, Tokyo 1 JAPON	an Kaikan EU (ED) 3-chome
	SAEKI & PARTNERS JA 900763

Date of mailing (day/month/year)
07 December 2006 (07.12.2006)

Applicant's or agent's file reference JA900763

International application No. PCT/JP2005/002981

IMPORTANT NOTIFICATION

International filing date (day/month/year)
24 February 2005 (24.02.2005)

**Applicant** 

JAPAN SCIENCE AND TECHNOLOGY AGENCY et al

1	Transmittal of the	translation	ťο	the a	nnlicant.
1.	Transmittai of the	uransmuon	w	шеа	ррисань

<b>V</b>	The International Bureau transmits herewith a copy of the English translation of the international preliminary report on
	patentability (Chapter I).

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

None

4

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Masashi Honda

Facsimile No. +41 22 338 82 70

Facsimile No. +41 22 338 82 70

### PATENT COOPERATION TREATY

## **PCT**

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference JA900763	FOR FURTHER ACTION	See item 4 below	
International application No. PCT/JP2005/002981	International filing date (day/month/year) 24 February 2005 (24.02.2005)	Priority date (day/month/year) 01 March 2004 (01.03.2004)	
International Patent Classification (8th See relevant information in Form F	h edition unless older edition indicated) PCT/ISA/237		
Applicant JAPAN SCIENCE AND TECHNOL	LOGY AGENCY		

1.	This international preliminary in International Searching Author	report on patentability (Chapter I) is issued by the International Bureau on behalf of the ity under Rule 44 bis.1(a).
2.	In the attached sheets, any refe	al of 4 sheets, including this cover sheet.  rence to the written opinion of the International Searching Authority should be read as a reference report on patentability (Chapter I) instead.
3.	This report contains indication	s relating to the following items:
	Box No. I	Basis of the report
•	Box No. II	Priority
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	Box No. IV	Lack of unity of invention
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
	Box No. VI	Certain documents cited
	Box No. VII	Certain defects in the international application
•	Box No. VIII	Certain observations on the international application
4.	The International Bureau will not, except where the applicar date (Rule 44bis .2).	communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but at makes an express request under Article 23(2), before the expiration of 30 months from the priority

Date of issuance of this report
29 November 2006 (29.11.2006)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 338 82 70

Date of issuance of this report
29 November 2006 (29.11.2006)

Authorized officer

Masashi Honda

e-mail: pt08@wipo.int

Form PCT/IB/373 (January 2004)

## PATENT COOPERATION TREATY

From the NTERNATIONAL SEARCHING AUTHORI	TY		VSLA
To:			PCT PTON
			EITTEN OPINION OF THE IONAL SEARCHING AUTHORITY  (PCT Rule 43bis.1)
·		Date of mailing (day/month/year)	
Applicant's or agent's file reference  JA900763	·	FOR FURTHER	ACTION See paragraph 2 below
International application No.	International filing date (a	lay/month/year)	Priority date (day/month/year)
PCT/JP2005/002981	24.02.2005	· ·	01.03.2004
International Patent Classification (IPC) or both  Applicant	LEGUCIEI CLESSIFICATION AND	· . :	
JAPAN SCIENCE AND TEC	CHNOLOGY AGE	ACY	
1. This opinion contains indications related	ting to the following items		
Box No. I Basis of the	•	· ·.	
Box No. II Priority		·	
1	shment of opinion with reg	eard to novelty, invent	tive step and industrial applicability
	ty of invention	,	
Reasoned st		1(a)(i) with regard to us supporting such sta	novelty, inventive step or industrial tement
	uments cited		
Box No. VII Certain defe	ects in the international app	plication	
Box No. VIII Certain obs	ervations on the internation	nal application	
International Preliminary Examining than this one to be the IPEA and the this International Searching Authority	Authority ("IPEA") except chosen IPEA has notified y will not be so considered	of that this does not apply the International But.  The properties of the IPE	ill be considered to be a written opinion of the oply where the applicant chooses an Authority other reau under Rule 66.1 bis(b) that written opinions of A, the applicant is invited to submit to the IPEA and a first report to the date of mailing of Form
written reply together, where appropriation PCT/ISA/220 or before the expiration For further options, see Form PCT/IS	priate, with amendments, n of 22 months from the pr	before the expiration	of of 3 months from the date of manning of a series
3. For further details, see notes to Form			
Name and mailing address of the ISA/JP		Authorized officer	•
·			•
Facsimile No.		Telephone No.	

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/JP2005/002981

Box	k No. I	Basis of this opinion
1.	With	regard to the language, this opinion has been established on the basis of the international application in the language in which it was unless otherwise indicated under this item.
		This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under
	-	Rule 12.3 and 23.1(b)).
2.	With	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed nation, this opinion has been established on the basis of:
	a.	type of material
 		a sequence listing
		table(s) related to the sequence listing
	ь. <b>b.</b>	format of material
		in written format
·		in computer readable form
	c.	time of filing/furnishing
<b>.</b>		contained in the international application as filed.
		filed together with the international application in computer readable form.
	•	furnished subsequently to this Authority for the purposes of search.
		is an annual as a sequence listing and/or table(s) relating thereto has been filed or
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as
		filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Ad	ditional comments:

ð.

	WRITT.			ļ.	ional application No.	
	INTERNATION	AL SEARCH	NOF THE ING AUTHORITY	PC	T/JP2005/00298	31
ox No. V	Resoned statemen	t under Rule	43bis.1(a)(i) with regard to nov	elty, inventive step	or industrial applicability;	
	itations and expla	nations suppo	orting such statement			
. Statement						
Novelty (N	n	Cl.:	1-12			YES
	,	<u> </u>				NO
	• *	Claims				
Inventive s	step (IS)	Claims	1-12			YE
		Claims	•			NO
						*
Industrial	applicability (IA)	Claims _	1-12			YE.
	•	Claims _				NO
3930	Media by Usin		niral Diamine", Angew.		-	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated N soleucine" desc	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselectives, the production of alloi	vely allylated N soleucine" desc	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated N soleucine" desc	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated N soleucine" desc	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated N soleucine" desc	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated N soleucine" desc	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated N soleucine" desc	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated N soleucine" desc	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated N soleucine" desc	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated No soleucine" described or the docume and in the art.	-acylhydrazines" descr cribed in claim 12 are	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	r the production the production of the doc	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated No soleucine" described or the docume and in the art.	-acylhydrazines" described in claim 12 are nts considered to be	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	method for of the doctors, nor o	niral Diamine", Angew.  uction of enantioselective  or the production of alloicuments cited in the ISR	vely allylated No soleucine" described or the docume and in the art.	-acylhydrazines" described in claim 12 are nts considered to be	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	method for of the doctors, nor o	uction of enantioselective the production of alloi cuments cited in the ISR byious to a person skille	rely allylated No soleucine" described for the docume and in the art.	-acylhydrazines" described in claim 12 are nts considered to be	
Aqueous 3930 T in claims	Media by Using the "method for 1-11 and the "escribed in any	method for of the doctors, nor o	uction of enantioselective the production of alloi cuments cited in the ISR byious to a person skille	rely allylated No soleucine" described for the docume and in the art.	-acylhydrazines" described in claim 12 are nts considered to be	